Technology Appraisal Committee Meeting (Committee [A])

Minutes: Confirmed

Date and Time: 19th July 2016

Venue: Prospero House
24 High Street
SE1 7DA

Present:
1. Dr Jane Adam Present for all notes
2. Dr Jeremy Braybrooke Present for all notes
3. Dr Justin Daniels Present for all notes
4. Dr Rachel Hobson Present for all notes
5. Dr Anne McCune Present for all notes
6. Professor John McMurray Present for all notes
7. Dr Mohit Misra Present for all notes
8. Mrs Sarah Parry Present for all notes
9. Ms Pamela Rees Present for all notes
10. Dr Paul Robinson*LT Present for all notes
11. Ms Ellen Rule*LT Present for all notes
12. Dr Brian Shine Present for all notes
13. Mr David Thomson*LT Present for all notes
14. Dr John Watkins Present for all notes
15. Professor Olivia Wu Present for all notes

In attendance:

Meindert Boysen Programme Director, National Institute for Health and Care Excellence Present for all notes

Janet Robertson Associate Director, National Institute for Health and Care Excellence Present for all notes

Liv Gualda Project Manager, National Institute for Health and Care Excellence Present for all notes

Marcia Miller Technology Appraisal Administrator, National Institute for Health and Care Excellence Present for all notes
Sana Khan  Technical Analyst,  
National Institute for  
Health and Care  
Excellence  
Present for notes 1 to 14

Zoe Charles  Technical Adviser,  
National Institute for  
Health and Clinical  
Excellence  
Present for notes 1 to 14

Joanna Richardson  Technical Adviser,  
National Institute for  
Health and Clinical  
Excellence  
Present for notes 17 to 26

ERG - SchARR  Paul Tappenden  School of Health Related Research  
Present for notes 1 to 14

Emma Simpson  School of Health Related Research  
Present for notes 1 to 14

Daniel Pollard  School of Health Related Research  
Present for notes 1 to 14

Experts  Dr Simon Rule  Consultant  
Haematologist  
Present for notes 1 to 14

Reta Brownlow  Patient expert  
Present for notes 1 to 14

Mr Jonathan Pearce  Patient expert  
Present for notes 1 to 14

Non-public observers:

Mike Chambers  Committee member

Heidi Livingstone  NICE, PPIP  
Present for notes all notes

Aminata Thiam  NICE, CHTE TA  
Present for notes all notes

Adam Storrow  NICE  
Present for notes all notes

Joshua South  NICE, corporate office  
Present for notes all notes
Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of Ibrutinib for treating relapsed or refractory mantle cell lymphoma.

2. The Chair informed the Committee of the non-public observers at this meeting: Mike Chambers, Heidi Livingstone, Aminata Thiam, Adam Storrow and Joshua South

3. Apologies were received from Dr Graham Ash, Dr Andrew England, Mr Adrian Griffin, Mr Stephen Sharp and Dr Nerys Woolacott.

Notes from the last meeting

4. Minutes of the last meeting were agreed

Appraisal of Ibrutinib for treating relapsed or refractory mantle cell lymphoma [ID753]

Part 1 – Open session

5. The Chair welcomed the invited experts: Mrs Reta Brownlow, Mr Jonathan Pearce Dr Simon Rule, Dr Paul Tappenden, Emma Simpson and Daniel Pollard to the meeting and they introduced themselves to the Committee.

6. The Chair welcomed company representatives from Janssen to the meeting.

7. The Chair asked all Committee members to declare any relevant interests

7.1. Dr Jane Adam, Dr Justin Daniels, Dr Anne McCune Professor John McMurray, Dr Mohit Misra, Mrs Sarah Parry, Miss Pamela Rees, Dr Paul Robinson, Ms Ellen Rule, Dr Brian Shine Mr David Thomson, Dr John Watkins and Professor Olivia Wu all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Ibrutinib for treating relapsed or refractory mantle cell lymphoma.

7.2. Dr Jeremy Braybrooke declared a non-personal non specific financial interest as is co-investigator on clinical trials in breast cancer with studies sponsored by comparator companies in this appraisal.

9.3.1 It was agreed that this declaration would not prevent Dr Jeremy Braybrooke from participating in this section of the meeting.
7.3. Dr Rachel Hobson declared a personal non-specific financial interest as she has sat on two advisory boards for Janssen in March/June 2015 in relation with diabetes.

9.2.1 It was agreed that this declaration would not prevent Dr Rachel Hobson from participating in this section of the meeting.

7.4. Mr Adrian Griffin declared a personal specific financial interest as Janssen is a Johnson and Johnson company. It was agreed that this declaration would prevent Mr Adrian Griffin from participating the meeting and he remained absent.

8. The Chair asked all NICE Staff to declare any relevant interests.

8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Ibrutinib for treating relapsed or refractory mantle cell lymphoma.

9. The Chair asked all other invited guests (ERG and invited experts, not including observers) to declare their relevant interests.

9.1. Paul Tappenden, Emma Simpson, Daniel Pollard all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Ibrutinib for treating relapsed or refractory mantle cell lymphoma

9.2. Mrs Reta Brownlow declared a non-personal specific financial interest as Bloodwise has received an unrestricted grant from Janssen, but not specifically in relation with this appraisal.

9.2.1. It was agreed that this declaration would not prevent Mrs Reta Brownlow from participating in this section of the meeting

9.3. Mr Jonathan Pearce declared a non-personal specific financial interest as Lymphoma Association has previously received some financial support from Janssen (the manufacturer of the treatment under appraisal).

9.3.1. It was agreed that this declaration would not prevent Mr Jonathan Pearce from participating in this section of the meeting

9.4. Dr Simon Rule declared a personal non-specific financial interest as he has sat on advisory boards for Janssen

9.4.1. It was agreed that this declaration would not prevent Dr Simon Rule from participating in this section of the meeting

9. The Chair introduced the lead team, Dr Paul Robinson, Ms Ellen Rule and Mr David Thomson who gave presentations on the clinical effectiveness and cost effectiveness of Ibrutinib for treating relapsed or refractory mantle cell lymphoma.
11. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

12. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

13. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

14. Discussion on confidential information continued. This information was supplied by the company.

15. The Committee continued to discuss the clinical and cost effectiveness of ibrutinib for treating relapsed or refractory mantle cell lymphoma

16. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.
Appraisal of Cobimetinib in combination with vemurafenib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma [ID815]

Part 1 – Open session

17. The Chair welcomed company representatives from Roche to the meeting.

18. The Chair asked all Committee members to declare any relevant interests

18.1. Dr Jane Adam, Dr Justin Daniels, Dr Anne McCune Professor John McMurray, Dr Mohit Misra, Mrs Sarah Parry, Ms Pamela Rees, Dr Paul Robinson, Ms Ellen Rule, Dr Brian Shine Mr David Thomson, Dr John Watkins and Professor Olivia Wu declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of cobimetinib in combination with vemurafenib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma.

18.2. Dr Jeremy Braybrooke declared a non-personal specific financial interest as he is a co-investigator on clinical trials in breast cancer with studies sponsored by comparator companies in this appraisal

9.2.1 It was agreed that this declaration would not prevent Dr Jeremy Braybrooke from participating in this section of the meeting.

19. The Chair asked all NICE Staff to declare any relevant interests.

19.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of cobimetinib in combination with vemurafenib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma

20. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

21. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

22. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
23. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

**Part 2 – Closed session**

24. Discussion on confidential information continued. This information was supplied by the company.

25. The Committee continued to discuss the clinical and cost effectiveness of cobimetinib in combination with vemurafenib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma [ID815]

26. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

**Date, time and venue of the next meeting**

27. 10am, Tuesday 16th August 2016 at NICE London Office, Prince of Wales Suite 10 Spring Gardens SW1A 2BU